Last updated: February 19, 2026
This report details the patent landscape surrounding Canadian patent CA2696627, focusing on its claims, scope, and potential implications for the pharmaceutical industry. The patent, titled "STABLE FORMULATIONS OF SOMATIC MUTATIONS ASSOCIATED WITH CANCER," was filed by Cepheid and granted on April 14, 2015. It addresses methods and compositions for stabilizing nucleic acids associated with somatic mutations in cancer.
What is the Core Invention Claimed in CA2696627?
The central invention claimed in CA2696627 pertains to the stabilization of nucleic acids, specifically those carrying somatic mutations indicative of cancer. The patent describes formulations that prevent or reduce the degradation of these target nucleic acid sequences within biological samples, thereby improving the accuracy and reliability of diagnostic tests.
The patent's claims are structured to cover both the methods of stabilizing nucleic acids and the compositions that achieve this stabilization. Key elements include:
- Stabilizing Agents: The claims identify various agents capable of stabilizing nucleic acids. These can include nucleases inhibitors, chelating agents, and other compounds that counteract degradation pathways.
- Target Nucleic Acids: The formulations are designed to protect nucleic acids that are indicative of somatic mutations associated with cancer. This encompasses DNA and RNA molecules carrying specific genetic alterations found in tumor cells.
- Biological Samples: The methods and compositions are intended for use with various biological sample types, such as blood, plasma, serum, tissue biopsies, and cell-free DNA (cfDNA).
- Diagnostic Applications: The ultimate purpose of the stabilization is to facilitate accurate and sensitive detection of cancer-related mutations, enabling improved diagnostic, prognostic, and therapeutic monitoring.
Claim 1, as an independent claim, provides a foundational description of the invention:
"A method for stabilizing nucleic acid in a biological sample comprising:
a) providing a biological sample suspected of containing nucleic acid;
b) contacting said biological sample with a composition comprising:
i) at least one nuclease inhibitor;
ii) at least one chelating agent; and
iii) a buffer effective to maintain a pH between 6 and 8." [1]
Dependent claims further refine the scope by specifying particular nuclease inhibitors, chelating agents, buffer compositions, and sample types. For instance, some claims may detail specific concentrations or combinations of these components, enhancing the specificity of the protection offered.
What is the Specific Scope of Protection Granted?
The scope of protection granted by CA2696627 is primarily focused on the chemical stabilization of nucleic acids within biological samples to detect cancer-related mutations. The patent does not claim the detection of specific mutations themselves, nor does it claim the therapeutic treatment of cancer. Instead, it claims the essential preparatory step that enhances the quality of the genetic material for downstream analysis.
The scope is defined by the specific limitations and features outlined in the claims. These include:
- Compositional Elements: The patent specifically enumerates the types of components that must be present in the stabilizing composition, namely nuclease inhibitors, chelating agents, and a buffer within a specified pH range.
- Method of Use: The claims cover the act of contacting the biological sample with this stabilizing composition. This implies that any process that involves mixing the sample with these specified stabilizing agents falls within the patent's purview.
- Purpose of Stabilization: While not directly claimed as a method of diagnosis, the context for the stabilization is clearly stated as being for the purpose of detecting somatic mutations associated with cancer. This intent influences the interpretation of the claims.
The patent's claims are deliberately broad in terms of the types of cancer mutations and the biological samples that can be used. This breadth allows for application across a wide range of cancer diagnostics. However, the novelty and inventiveness lie in the specific combination of stabilizing agents and the buffering system to achieve enhanced nucleic acid integrity for mutation analysis.
How Does CA2696627 Fit into the Broader Diagnostics Patent Landscape?
Canadian patent CA2696627 occupies a crucial niche within the diagnostics patent landscape, particularly concerning molecular diagnostics for oncology. Its focus on sample preparation and stabilization is foundational to the entire field of liquid biopsy and precision medicine.
The landscape can be broadly categorized into several overlapping areas:
- Biomarker Discovery: Patents in this area cover the identification of novel genetic markers, proteins, or other biological indicators of cancer. CA2696627 does not claim discovery of biomarkers.
- Assay Development: This includes patents on specific methods and kits for detecting biomarkers, such as PCR-based assays, next-generation sequencing (NGS) panels, or microarrays. CA2696627 supports these assays by providing stabilized samples.
- Sample Collection and Preparation: This is the domain of CA2696627, focusing on preserving the integrity of biological material for analysis. Patents here often involve specialized collection tubes, preservatives, or stabilization solutions.
- Diagnostic Systems and Software: Patents relating to integrated diagnostic platforms, data analysis algorithms, and reporting software used to interpret test results.
CA2696627 is a foundational patent within the "Sample Collection and Preparation" category. Its claims are directed at improving the reliability of assays developed by others. Companies operating in cancer diagnostics, especially those utilizing liquid biopsies where cfDNA/RNA integrity is paramount, are likely to encounter this patent.
Comparison with Related Patenting Areas:
| Patent Category |
Description |
Relevance to CA2696627 |
| Biomarker Discovery |
Identification of novel genetic mutations or proteins as indicators of cancer. |
CA2696627 stabilizes samples containing nucleic acids that may carry these mutations. It does not claim the mutations themselves. |
| Assay Development (e.g., PCR, NGS) |
Development of specific methods and kits to detect genetic mutations. |
CA2696627 is complementary to assay patents, providing enhanced sample quality for more accurate and sensitive assay performance. |
| Sample Stabilization |
Patents focused on methods and compositions to preserve biological samples and their analytes. |
CA2696627 is a prime example of a patent in this category, specifically addressing nucleic acid stabilization for cancer mutation detection. |
| Therapeutic Applications |
Patents related to treatments for cancer, including targeted therapies based on genetic profiles. |
While CA2696627 supports precision medicine by enabling better diagnostics, it does not claim any therapeutic interventions. |
| Data Analysis & Interpretation |
Patents covering the algorithms and software used to analyze genetic data and provide diagnostic reports. |
CA2696627 aims to improve the input data quality for these analysis systems, leading to more reliable interpretation. |
The patent's claims are specific enough to define a distinct invention while broad enough to encompass a range of commercially relevant applications in cancer diagnostics. Competitors developing sample stabilization solutions for cancer mutation testing would need to assess their technologies against the claims of CA2696627.
Who Holds the Patent Rights, and What is Their Strategic Position?
The patent rights for CA2696627 are held by Cepheid. Cepheid is a prominent company in the field of molecular diagnostics, known for its GeneXpert systems, which offer rapid and automated nucleic acid testing. Their strategic position is to leverage intellectual property in critical areas that underpin the performance and reliability of diagnostic tests.
Strategic Implications for Cepheid:
- Enabling Technology: By patenting sample stabilization, Cepheid secures a foundational element for molecular diagnostic workflows. This technology is crucial for the accuracy of tests performed on their platforms and potentially for other diagnostic systems.
- Competitive Barrier: The patent creates a barrier to entry for competitors developing similar sample stabilization solutions for cancer mutation detection. This can encourage licensing agreements or necessitate the development of alternative, non-infringing technologies.
- Integration with Product Portfolio: Cepheid's diagnostic tests, especially those related to oncology, benefit from the improved sample quality offered by their patented stabilization methods. This enhances the performance claims of their diagnostic products.
- Licensing Opportunities: The patent may present licensing opportunities for other diagnostic companies that wish to use Cepheid's stabilization technology in their own assays or sample collection devices.
Potential Implications for Competitors:
- Freedom-to-Operate (FTO) Analysis: Companies developing or marketing cancer diagnostic kits, particularly those involving liquid biopsies or requiring high nucleic acid integrity, must conduct thorough FTO analyses to determine if their products infringe on CA2696627.
- Technology Development: Competitors may need to innovate and develop alternative stabilization chemistries or methods that do not fall within the scope of Cepheid's claims.
- Strategic Partnerships: Some companies might seek licensing agreements with Cepheid to utilize their patented technology, particularly if it offers a significant performance advantage.
Cepheid's ownership of CA2696627 places them in a position to influence the market for sample preparation in cancer diagnostics, impacting how samples are collected, processed, and analyzed for genetic mutations.
What are the Key Technical Aspects and Limitations of the Patent?
The key technical aspects of CA2696627 revolve around the specific chemical components and their synergistic effect in preserving nucleic acid integrity. The limitations are primarily defined by the specific wording of the claims, which delineate the precise scope of protection.
Key Technical Aspects:
- Synergistic Stabilization: The patent emphasizes the combination of at least one nuclease inhibitor, at least one chelating agent, and a buffer within a specific pH range (6-8). The synergy between these components is crucial for effective stabilization.
- Nuclease Inhibition: Nuclease inhibitors prevent the enzymatic breakdown of DNA and RNA. The patent likely encompasses various classes of these inhibitors, which could include EDTA (also a chelating agent), proteinase K, or other specific molecular agents designed to block nuclease activity.
- Chelating Agents: These agents, such as EDTA, bind metal ions (e.g., Mg++, Ca++) that are cofactors for many nucleases. By sequestering these ions, chelating agents indirectly inhibit nuclease activity.
- Buffering System: Maintaining a stable pH between 6 and 8 is critical. This pH range is generally optimal for nucleic acid stability and can also influence the activity of certain nucleases and the efficacy of other formulation components.
- Broad Applicability: The formulations are designed to be effective across a range of biological samples and for various types of somatic mutations, making them versatile for different diagnostic applications.
Limitations:
- Specific Component Requirements: The claims are tied to the presence of the enumerated components. Formulations lacking one or more of these key elements (nuclease inhibitor, chelating agent, specific pH buffer) may not infringe.
- Scope of "Nuclease Inhibitor" and "Chelating Agent": While the patent lists categories, the specific identity and efficacy of these compounds can be subject to interpretation. The claims do not necessarily cover all possible nuclease inhibitors or chelating agents, but rather those used in the context of the claimed invention.
- Exclusion of Detection Methods: The patent explicitly focuses on the stabilization of nucleic acids, not the detection methods themselves. Therefore, it does not prevent others from developing novel detection assays as long as they do not utilize the patented stabilization process.
- Prior Art and Inventive Step: Like all patents, CA2696627 is subject to examination against prior art. The validity of the patent relies on demonstrating that the claimed invention was novel and involved an inventive step at the time of filing. Future challenges could be based on prior art that anticipates or renders obvious the claimed stabilization methods.
- Geographic Limitation: The patent is exclusively valid within Canada. Its scope does not extend to other jurisdictions unless similar patents are granted elsewhere.
Understanding these technical aspects and limitations is vital for assessing infringement risks and for developing alternative technologies.
How Can Companies Navigate the Patent Landscape and Ensure Freedom to Operate?
Navigating the patent landscape surrounding CA2696627 requires a proactive and systematic approach focused on understanding intellectual property rights and their implications for product development and commercialization. Companies must prioritize rigorous assessment and strategic planning.
Key Strategies for Navigation and Freedom to Operate (FTO):
-
Comprehensive Patent Searching and Analysis:
- Conduct thorough searches for patents related to nucleic acid stabilization, sample preservation, cancer diagnostics, and liquid biopsy technologies in Canada and other relevant jurisdictions.
- Analyze the claims of CA2696627 and any granted patents in key markets (e.g., U.S., Europe) owned by Cepheid or its competitors.
- Utilize patent databases and specialized intellectual property analytics tools.
-
Detailed Freedom-to-Operate (FTO) Opinion:
- Engage qualified patent counsel to obtain a formal FTO opinion. This opinion assesses whether a company's planned product or process infringes on existing patents.
- The FTO analysis should specifically consider the claims of CA2696627 in relation to the company's technology, including the composition of their sample stabilization solutions and their intended use.
-
Claim Construction and Interpretation:
- Carefully dissect the wording of the claims in CA2696627. Understand the meaning of terms such as "nuclease inhibitor," "chelating agent," and "biological sample" within the context of patent law.
- Consider potential variations and equivalents that might be covered under the doctrine of equivalents.
-
Competitor Landscape Monitoring:
- Continuously monitor patent filings and granted patents by key players in the molecular diagnostics and oncology space, particularly Cepheid.
- Track litigation and licensing activities related to relevant patents.
-
Technological Innovation and Differentiation:
- Focus R&D efforts on developing novel sample stabilization technologies that are distinct from the claims of CA2696627.
- This could involve exploring different classes of stabilizers, unique buffering systems, or alternative approaches to nucleic acid preservation.
- Document all inventive steps and prior art to support future patent applications and defend against potential challenges.
-
Strategic Licensing and Agreements:
- If a company's technology closely aligns with or relies upon the claims of CA2696627, explore licensing opportunities with Cepheid.
- Negotiate licensing terms that are commercially viable and provide adequate protection.
-
Patent Validity Assessment:
- Assess the strength and validity of CA2696627 by identifying potential prior art that may not have been considered during its examination.
- If a strong case can be made for invalidity, consider challenging the patent.
-
Documentation and Record Keeping:
- Maintain meticulous records of all R&D activities, including design-around efforts, experimental data, and internal legal assessments. This documentation is crucial for defending against infringement claims.
By implementing these strategies, companies can proactively manage their intellectual property risks, ensure their products can be commercialized without infringing on existing patents like CA2696627, and maintain a competitive edge in the dynamic field of cancer diagnostics.
Key Takeaways
Canadian patent CA2696627, held by Cepheid, protects methods and compositions for stabilizing nucleic acids in biological samples to improve the detection of somatic mutations associated with cancer. The patent's core innovation lies in the synergistic use of nuclease inhibitors, chelating agents, and a specific pH buffering system. Its scope is limited to the stabilization process and its components, not the discovery of biomarkers or the diagnostic assays themselves. Companies operating in cancer diagnostics, particularly those using liquid biopsies, must conduct thorough freedom-to-operate analyses and may need to develop alternative stabilization technologies or seek licenses to navigate this patent. Cepheid's strategic position is strengthened by owning this foundational intellectual property, potentially creating barriers for competitors and enhancing the performance of its own diagnostic offerings.
FAQs
-
Does CA2696627 claim the detection of cancer mutations?
No, CA2696627 does not claim the detection of cancer mutations. It claims the methods and compositions used to stabilize nucleic acids within biological samples, which is a preparatory step for mutation detection assays.
-
What types of biological samples are covered by this patent?
The patent covers various biological samples suspected of containing nucleic acid, which can include blood, plasma, serum, tissue biopsies, and cell-free DNA.
-
Can a company develop its own cancer diagnostic test without infringing CA2696627?
A company can develop its own cancer diagnostic test if its method for preparing the biological sample does not infringe on the specific claims of CA2696627. This typically involves avoiding the combination of nuclease inhibitors, chelating agents, and the specified pH buffer as claimed. A freedom-to-operate analysis is recommended.
-
What is the expiration date of Canadian patent CA2696627?
Canadian patent CA2696627 was granted on April 14, 2015. Patents in Canada typically have a term of 20 years from the filing date, provided maintenance fees are paid. The filing date for this patent was May 22, 2009 (corresponding to the international filing date of PCT/US2009/044786). Therefore, the patent is expected to expire around May 22, 2029.
-
Can this patent be licensed by other diagnostic companies?
Yes, patent holders like Cepheid can choose to license their intellectual property to other companies. Companies interested in utilizing the stabilization technology covered by CA2696627 would need to negotiate a licensing agreement with Cepheid.
Citations
[1] Cepheid. (2015). Stable Formulations of Somatic Mutations Associated with Cancer. Canadian Patent CA2696627. (Original filing date: May 22, 2009; Grant date: April 14, 2015).
